Key Development

Sun Pharmaceutical Industries Limited announced that UNLOXCYT® (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network® (NCCN®) Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or curative radiation. This represents an addition to the existing Category 2A designation in metastatic cutaneous squamous cell carcinoma (mCSCC) that was assigned to UNLOXCYT in 2025.

Product Background

UNLOXCYT was approved by the U.S. Food and Drug Administration (FDA) in 2024 and is indicated for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation. The recommended dosage is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks. UNLOXCYT is described as the first and only FDA-approved PD-L1-blocking antibody for advanced CSCC (aCSCC).

Clinical Evidence

The evidence submitted to NCCN was based on the pivotal registration study, which showed:

  • 55% of patients achieved an objective response
  • 26% achieved a complete response
  • Median follow-up of 24.1 months
  • Median duration of response had not been reached (range: 8.3 to 31.3+ months)
  • Fewer than 1% of patients experienced high-grade (Grade 3-5) immune-mediated adverse reactions
  • No grade 4 or 5 immune-mediated adverse reactions occurred

Executive Commentary

Ahmad Naim, MD, Senior Vice President, North American Chief Medical Officer, Sun Pharma, stated that the NCCN Guidelines help physicians evaluate appropriate treatment options and that this elevation validates the growing clinical evidence supporting UNLOXCYT.

Dr. Francis Worden, Clinical Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, noted that the guideline update reflects the strength of published evidence supporting UNLOXCYT as first-line treatment for laCSCC, highlighting durable responses and low incidence of high-grade adverse reactions.

Mark Gimbert, Senior Vice President, Head of Market and Patient Access, North America, Sun Pharma, emphasized that NCCN recognition helps ensure appropriate patients can receive this treatment without unnecessary access barriers.

Market Access Impact

NCCN Guidelines have a meaningful impact on patient access as they inform payer coverage policies, prior-authorization criteria, institutional formularies, and clinical pathways.

Disease Context

Cutaneous squamous cell carcinoma (CSCC) is among the most common skin cancers worldwide, with an estimated 40,000 US patients each year progressing to advanced disease, resulting in nearly 15,000 deaths. Important risk factors include chronic ultraviolet radiation exposure and immunosuppressive conditions.

Company Background in Oncology

Sun Pharma has built on its leadership in dermatology for over two decades to advance care for people impacted by skin cancer, with a dedicated cutaneous oncology team and growing focus in specialty medicines.

Safety Information

The document includes extensive important safety information covering warnings and precautions for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity. The most common adverse reactions (≥10%) include fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritus, edema, localized infection, and urinary tract infection.

Financial Impact

Financial impact not quantified in the disclosure.